RxDoctor Payments Data

Puneet Agarwal, MD

Critical Care Medicine · Raleigh, NCNPI 1780905059

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $654 of the $803 with a category attached, or 81.5%. 10 manufacturers reported payments, led by Boehringer Ingelheim at 43.6% of the total. Reporting peaked in 2021 at $189 and has fallen 65.5% since, to $65 in 2025.

$803in general payments, 2019–2025

Across 31 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$350
  • Boston Scientific$110
  • Sunovion Pharmaceuticals Inc.$75
  • Insmed, Inc.$71
  • AbbVie$40
  • Novartis$37
  • plus $120 from 4 others

What the payments were for

  • Food & beverage$65482%
  • Education$14818%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$803 in reported general payments places this provider in the 65th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$61,576
Medicare patients
267
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$85,079
Breo ElliptaFluticasone/Vilanterol44$28,058
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$19,726
Spiriva RespimatTiotropium Bromide30$17,396
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,979
Incruse ElliptaUmeclidinium Bromide20$8,354
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$6,150
Advair HfaFluticasone Propion/Salmeterol15$5,445
Arnuity ElliptaFluticasone Furoate17$4,786
SymbicortBudesonide/Formoterol Fumarate14$4,543
Albuterol Sulfate HfaAlbuterol Sulfate23$376
Prednisone44$106
Azithromycin13$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$35$146,005233 claims
Boehringer IngelheimSpiriva Respimat$350$17,39630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →